{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"400"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"description":"Will be defined as the dose level below the lowest dose that induces dose-limiting toxicity in at least 1/3 of patients, as assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0.","groups":[{"description":"INDUCTION THERAPY: Patients receive ixazomib citrate PO on days 1, 8, and 15 and cyclophosphamide PO and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.\\> \\>\\>\n\n\\>\n\n\\>\\> MAINTENANCE THERAPY: Patients receive ixazomib citrate PO on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\\>\n\n\\>\\>\n\n\\>\n\n\\>\\> Cyclophosphamide: Given PO\\>\n\n\\>\\>\n\n\\>\n\n\\>\\> Dexamethasone: Given PO\\>\n\n\\>\\>\n\n\\>\n\n\\>\\> Ixazomib Citrate: Given PO\\>\n\n\\>\\>\n\n\\>\n\n\\>\\> Laboratory Biomarker Analysis: Correlative studies\\>\n\n\\>\\>\n\n\\>\n\n\\>\\> Pharmacological Study: Correlative studies\\>\n\n\\>\\>\n\n\\>\n\n\\>\\> Quality-of-Life Assessment: Ancillary studies\\>\n\n\\>\\>\n\n\\>\n\n\\>\\> Questionnaire Administration: Ancillary studies","id":"OG000","title":"Treatment (Ixazomib Citrate, Cyclophosphamide, Dexamethasone)"}],"paramType":"NUMBER","populationDescription":"The 10 patients accrued to the phase I portion of the study were analyzed to determine the maximum tolerated dose of ixazomib with cyclophosphamide and dexamethasone","reportingStatus":"POSTED","timeFrame":"At 28 days","title":"Maximum Tolerated (MTD) Dose of Cyclophosphamide (Phase I)","type":"PRIMARY","unitOfMeasure":"mg/m² weekly"}